Table 2:
Baseline patient characteristics and comorbid conditions in patients with 12-month follow-up after continued appropriate medical therapy (n=59)
| Characteristics: | Mean [±SD] | Range | N (%) |
|---|---|---|---|
| Age at enrollment (years) | 56.5 [±12.6] | (33 – 82) | ----- |
| Males* | ----- | ----- | 28 (48%) |
| White/Caucasian | ----- | ----- | 53 (90%) |
| African American | ----- | ----- | 3 (5%) |
| Asian | ----- | ----- | 1 (2%) |
| Hispanic/Latino | ----- | ----- | 1 (2%) |
| Nasal polyposis | ----- | ----- | 24 (41%) |
| Turbinate hypertrophy | ----- | ----- | 3 (5%) |
| Asthma | ----- | ----- | 21 (36%) |
| AERD/ASA intolerance | ----- | ----- | 5 (9%) |
| Allergic rhinitis^ | ----- | ----- | 21 (36%) |
| Depression* | ----- | ----- | 4 (7%) |
| Current tobacco use/smoking | ----- | ----- | 0 (0%) |
| Current alcohol use | ----- | ----- | 34 (58%) |
| Diabetes mellitus (Type I / II) | ----- | ----- | 5 (9%) |
| SNOT-22 total score: | 40.1 [±14.8] | (8 – 80) | ----- |
| Rhinologic symptoms | 13.8 [±6.1] | (1 – 27) | ----- |
| Extra-nasal rhinologic symptoms | 7.1 [±3.2] | (0 – 12) | ----- |
| Ear/facial symptoms | 7.3 [±4.8] | (0 – 19) | ----- |
| Psychological dysfunction | 10.5 [±5.8] | (0 – 23) | ----- |
| Sleep dysfunction | 9.9 [±5.7] | (0 – 24) | ----- |
*
identified through self-report;
^
confirmed via modified radioallergosorbent or skin prick testing; CRS, chronic rhinosinusitis; SD, standard deviation; N, sample size; AERD, aspirin exacerbated respiratory disease; ASA, acetylsalicylic acid; SNOT-22, 22-item SinoNasal Outcome Test.